Pay in 4 interest-free payments of $5.18 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Patients taking Ozempic may experience disruption to normal digestive processes due to delayed gastric emptying and altered gut transit time
Date of publication September 1, 2025 Keyword long-term comparative effectiveness control effects of once-weekly subcutaneous semaglutide treatment outcomes patient-reported outcomes analysis findings USA T2D adult population treatment intensification safety years open-label participants HbA body data medication concerns primary endpoint study therapy changes proportion antidiabetic medications missing data clinical trials safety concerns trials proportion of participants year 2 reduction clinical practice decrease practice glycemic control individuals alternative treatment randomized pragmatic clinical trial improvement adults year 1 long-term effects pragmatic clinical trials population weight once-weekly subcutaneous semaglutide semaglutide add-on therapy subcutaneous semaglutide body weight inadequate glycemic control endpoint oral antidiabetic medications treatment changes associated with large reductions once-weekly semaglutide US adult population type 2 diabetes type intensification DOI Identifier Dimensions ID: pub.1193938300 DOI: PMID: 41093600 Resource type Article Rights statement In Copyright License Attribution-NonCommercial 4.0 International Journal title BMJ Open Diabetes Research & Care Journal volume 13 Journal issue 5 Page start e005161 Version Publisher Funder Novo Nordisk AS ISSN 2052-4897 Publisher BMJ Relations Parents: This work has no parents.
The FDA first approved tirzepatide in May 2022 for type 2 diabetes, carrying the brand name Mounjaro
Quantitative proteomic analyses of human cytomegalovirus-induced restructuring of endoplasmic reticulum-mitochondrial contacts at late times of infection
